Skip to content

Contact +44 (0) 20 7060 7474 email us

Vaccines

Vaccines Market Insight

Products, Pipelines & Market Outlook

Publication Date January 2007
Publisher Scrip Reports
Product Type Report
Pages not applicable
ISBN Number not applicable
Product Code SCR00024

Price

£1,095.00
approximately: $1,816 | €1,204

pdf

Buy Now

Order above formats by FAX

Order by Fax

Summary

The European market for medical devices is the second largest in the world after the US and is forecast to be worth approximately €55.2 billion in 2006.

However, despite the aims of the EU to bring about some sort of harmonization between the laws of its individual Member States there are still a great many variations between the individual nations with regards to how their health services are operated and the manner in which medical device companies must approach them to sell products.

The situation within the EU was made even more complicated by the accession of ten new Member States in 2004. In order to gain entry to the EU, and receive all the benefits that open access to this huge market provides, the new Member States had to show that their legislation and internal governing structures were brought into line with those of the rest of the EU. While this caused a number of reforms in the structures of the nations' health systems, the story did not end with accession. Indeed gaining entry to such a large market has proved to be a double-edged sword for some countries as increased competition and increased access to their home markets from larger and frequently more sophisticated medical market players has caused the costs within their health services to soar. As a result many of the new entrants to the EU are currently undergoing further reforms to their health systems in an attempt to rationalise their services and bring their costs down.

The state of affairs in the health systems of the older members of the EU is not that different to those of the newer members. Although the overhaul of their health system organisations may not be as radical or sudden, they are still under pressure to reduce costs and increase efficiency and are implementing schemes to rationalise their approaches to healthcare provision.

The processes of reform have some commonalities and some differences.

Many are introducing forms of classification based on diagnosis related groups (DRGs) to track and allocate resources, health technology assessment procedures to evaluate the efficiency of technologies and increased accountability of healthcare insurers. However whereas some countries are seeing the decentralisation of processes as a means to introduce increased competition and so reduce prices, others are bringing them under more central control in order that they can be better monitored.

As the health budgets allocated to health systems within each nation very infrequently have large changes in the levels of investment, this situation is akin to cutting the same cake up in different ways to see if it can be made to look bigger and stretch further.

The structures of the health systems affect the purchasing decisions and purchasing mechanisms for medical devices within a country, and although there are some similarities brought about through membership of the EU such as the provisions for public tendering, given in Directive 93/36/EEC of 14 June 1993, there are many differences. For example in Belgium, all medical procedures and devices are reimbursed on the basis of a national list, the Nomenclature INAMI/RIZIV whereas in the Netherlands there is no such list.

Dr Mark Charny, managing director of Translucency Ltd, a consultancy specialising in supporting medical device and pharmaceutical clients to obtain funding for their products in the EU, sums up the situation thus:

"Reimbursement depends very much on the product being discussed.

Therefore if a client came to me and said, 'I am a manufacturer of scalpel blades and I want to sell them and be reimbursed for them in the UK,' what I would say to them would be very different to what I would have to tell a customer who wanted to be reimbursed for a drug eluting stent. And that's just the situation for the UK; each other country has major differences in how they treat products.

Despite this there are some commonalities:

Clinicians have less say in the decision making process of purchases.

They can say no, but they cannot say yes to a purchase.

Health technology assessment is having more of a profound effect.

The same pressures are on every market and generally the fundamental dynamics of all reimbursement systems are the same, therefore if a set of questions is drawn up to assess the reimbursement potential for a product in the UK the answers will do for Germany and Spain as well. That is not to say that do not have to be put into a different format and submit them to different people, but the questions are the same. These questions are essentially how much does it cost, how well does it do its job and how much evidence is there to support those claims."

This report assesses the major routes of procurement and the reimbursement mechanisms that are in operation in each of the 25 EU Member States and two candidate countries (Bulgaria and Romania) as well as discussing the structure and size of the individual markets, which act as positive spurs or negative pressures to medical device and diagnostics reimbursement.

This report is an extension of the Clinica Report Gaining Reimbursement for Medical Devices and Diagnostics 2004 (CBS 924) and the authors of that report were contacted to gain an insight into the changes that have taken place in the European markets that it covered: Germany, France, Italy, Spain and the UK. In addition consultants, analysts, national health and medical associations, statistical databases, and journals were consulted in each of the other Member States to create this profile of the EU.

The report aims to help you meet the challenges represented by each country's unique reimbursement requirements, by describing each system and although reimbursement is an issue that has traditionally been limited to the marketing and accounting departments of companies; in the current changing environment it is an issue that should be disseminated and understood by all the members of a company. This report is therefore of importance to all medical device and diagnostic company employees, but its specific target is the executive officers, product development, marketing and sales personnel of medical device and diagnostic companies who should be working together to incorporate an understanding of reimbursement within the process that leads from product conception through to product distribution.

For each country this report provides a review of:

The medical device market The structure of the healthcare system Current and future reforms The reimbursement structure Key contacts for reimbursement issues

Contents

  • Chapter 1 Introduction
    • 1.1 Vaccines
    • 1.1.1 General
    • 1.1.2 A Brief History
    • 1.2 The Immune System
    • 1.2.1 Introduction
    • 1.2.2 Mch Markers
    • 1.2.3 Lymphocytes
    • 1.2.4 B Cells and T Cells
    • 1.2.5 Cytokines and Chemokines
    • 1.2.6 Phagocytes and Granulocytes
    • 1.2.7 Complement Proteins
    • 1.2.8 When The Immune System Fails
    • 1.3 Immunological Aspects of Cancer
    • 1.3.1 Introduction
    • 1.3.2 The Development of A Tumour
    • 1.3.3 The Treatment of Cancer
    • 1.4 Immunisation
    • 1.5 Types of Vaccine
    • 1.5.1 Prophylactic Vaccines
    • 1.5.2 Therapeutic Vaccines
    • 1.5.3 Recombinant Vaccines
    • 1.5.4 DNA Vaccines
    • 1.5.5 Autologous and Allogenic Vaccines
    • 1.5.6 Attenuated Live Vaccines
    • 1.5.7 Inactivated Killed Vaccines
  • Chapter 2 The Vaccines Market
    • 2.1 The Vaccines Market Today
    • 2.2 The Potential for Change
    • 2.3 Market Size
    • 2.4 Major Players
    • 2.4.1 Glaxosmithkline (Gsk)
    • 2.4.1.1 Company Background
    • 2.4.1.2 Products
    • 2.4.1.3 Cervarix
    • 2.4.1.4 Other Cancer Candidates
    • 2.4.1.5 Other Products in The Pipeline
    • 2.4.2 Merck & Co
    • 2.4.2.1 Company Background
    • 2.4.2.2 Gardasil
    • 2.4.2.3 Other Launched Products
    • 2.4.2.4 Products in The Pipeline
    • 2.4.3 Novartis
    • 2.4.3.1 Company Background
    • 2.4.3.2 Novartis' Influenza Vaccine Pipeline
    • 2.4.3.3 Other Products in The Pipeline
    • 2.4.4 Sanofi-Aventis
    • 2.4.4.1 Company Background
    • 2.4.4.2 Cancer Vaccine Products
    • 2.4.4.3 Other Vaccine Products
    • 2.4.5 Wyeth
    • 2.4.5.1 Company Background
    • 2.4.5.2 Launched Products
    • 2.4.5.3 Products in The Pipeline
    • 2.5 The Importance of Cancer Vaccines in The Overall Market
    • 2.6 Marketed Cancer Vaccines
    • 2.6.1 Cervarix - Glaxosmithkline
    • 2.6.2 Gardasil - Merck & Co
    • 2.6.3 M-Vax - Avax Technologies
    • 2.6.4 Theracys - Sanofi Pasteur
    • 2.6.5 Bacillus Calmette-Guerin (Bcg) Vaccine - Gsk
    • 2.6.6 Melacine - Gsk
    • 2.7 Other Marketed Vaccines
    • 2.7.1 Combination Vaccinations
    • 2.7.2 Hepatitis B
    • 2.7.3 Hepatitis A
    • 2.7.4 Influenza
    • 2.7.4.1 Flumist - Aviron (Now Astrazeneca)
    • 2.7.4.2 Fluviron/Flu-Immune - Powderject
    • Pharmaceuticals (Now Novartis)
    • 2.7.4.3 Fluviral - Id Biomedical (Now Gsk)
    • 2.7.4.4 Fluzone - Sanofi Pasteur
    • 2.7.4.5 Inflexal V and Nasalflu - Crucell
    • 2.7.4.6 Laiv - The Institute of Experimental Medicine,
    • St Petersburg, Russia
    • 2.7.4.7 Other Marketed Influenza Vaccines
    • 2.7.5 Haemophilus Influenzae Type B (Hib)
    • 2.7.6 Pertussis
    • 2.7.7 Rabies
    • 2.7.8 Typhoid
    • 2.7.9 Varicella and Zoster
    • 2.7.10 Meningitis
    • 2.7.10.1 Meningitis (Non-Specific)
    • 2.7.10.2 Meningitis A
    • 2.7.10.3 Meningitis B
    • 2.7.10.4 Meningitis B/C
    • 2.7.10.5 Meningitis C
    • 2.7.11 Pneumococcus
    • 2.7.12 Poliomyelitis
    • 2.7.13 Mmr and Measles and Rubella
    • 2.7.14 Smallpox
    • 2.7.15 Other Indications
    • 2.7.15.1 Cholera
    • 2.7.15.2 Rotavirus
    • 2.7.15.3 Epidemic Haemorrhagic Fever
    • 2.7.15.4 Japanese Encephalitis (Je)
    • 2.7.15.5 Lactobacillus
    • 2.7.15.6 Yellow Fever
    • 2.7.15.7 Tick Borne Encephalitis (Tbe)
    • 2.7.15.8 Q Fever
    • 2.7.15.9 Ribosomal Vaccine
    • 2.7.15.10 Urinary Infection
    • 2.7.16 Launched Therapeutic Vaccines
    • 2.7.16.1 Leprovac
    • 2.7.16.2 Fluarix
    • 2.7.16.3 Solcotrichovac
    • 2.7.16.4 Pcec
    • 2.7.17 Withdrawn Vaccines
  • Chapter 3 Challenges and Opportunities
    • 3.1 Introduction
    • 3.2 Unmet Needs
    • 3.2.1 Cancer
    • 3.2.2 Hiv/Aids
    • 3.2.3 Autoimmune Diseases
    • 3.2.3.1 Asthma
    • 3.2.3.2 Diabetes Mellitus (Type 1)
    • 3.2.3.3 Rheumatoid Arthritis (Ra)
    • 3.2.4 Infectious Disease
    • 3.2.4.1 Tuberculosis (Tb)
    • 3.2.4.2 Meningitis
    • 3.2.5 Malaria
    • 3.2.6 Bioterrorism Threat
    • 3.2.7 Addiction
    • 3.2.8 Hepatitis C (Hcv)
    • 3.2.9 CNS - Alzheimer's Disease
    • 3.3 Technical Challenges
    • 3.3.1 Alternatives to Egg-Grown Vaccines
    • 3.3.2 Alternatives to Needles
    • 3.3.3 Problems with Supply and Storage of Vaccines
    • 3.3.4 Reducing The Number of Vaccinations
    • 3.4 Commercial Challenges
    • 3.4.1 Research and Development
    • 3.4.2 Economies of Scale
    • 3.4.3 Public Opinion
  • Chapter 4 Vaccines in Development
    • 4.1 Cancer
    • 4.1.1 Introduction
    • 4.1.2 Registered or Awaiting Approval
    • 4.1.3 Cancer Vaccines in Phase Iii Clinical Development
    • 4.1.3.1 Brain Cancer
    • 4.1.3.2 Hpv
    • 4.1.3.3 Lung Cancer and Nsclc
    • 4.1.3.4 Lymphoma
    • 4.1.3.5 Pancreas Cancer
    • 4.1.3.6 Prostate Cancer
    • 4.1.3.7 Renal Cancer
    • 4.1.4 Cancer Vaccines in Phase Ii Clinical Development
    • 4.1.4.1 General
    • 4.1.4.2 Brain Cancer
    • 4.1.4.3 Breast Cancer
    • 4.1.4.4 Cervical Cancer
    • 4.1.4.5 Colorectal Cancer
    • 4.1.4.6 Leukaemia
    • 4.1.4.7 Lung Cancer and Nsclc
    • 4.1.4.8 Lymphoma
    • 4.1.4.9 Melanoma
    • 4.1.4.10 Myeloma
    • 4.1.4.11 Prostate Cancer
    • 4.1.4.12 Renal Cancer
    • 4.1.5 Cancer Vaccines in Phase I Clinical Development
    • 4.1.5.1 Multiple or Unspecified Targets
    • 4.1.5.2 Bladder Cancer
    • 4.1.5.3 Brain Cancer
    • 4.1.5.4 Breast Cancer
    • 4.1.5.5 Head and Neck Cancer
    • 4.1.5.6 Liver Cancer
    • 4.1.5.7 Lung and Nsclc Cancer
    • 4.1.5.8 Oesophageal Cancer
    • 4.1.5.9 Ovarian and Pancreatic Cancers
    • 4.1.5.10 Prostate Cancer
    • 4.1.6 Cancer Vaccines in Preclinical Development
    • 4.1.6.1 Non-Specified Cancers
    • 4.1.6.2 General Cancer Targets
    • 4.1.6.3 Bone Cancer
    • 4.1.6.4 Breast Cancer
    • 4.1.6.5 Colorectal and Colon Cancer
    • 4.1.6.6 Gastric Cancer
    • 4.1.6.7 Hpv
    • 4.1.6.8 Leukaemia
    • 4.1.6.9 Liver Cancer
    • 4.1.6.10 Lung Cancer and Nsclc
    • 4.1.6.11 Melanoma
    • 4.1.6.12 Myeloma
    • 4.1.6.13 Ovarian Cancer
    • 4.1.6.14 Pancreatic Cancer
    • 4.1.6.15 Prostate Cancer
    • 4.1.6.16 Renal Cancer
    • 4.2 Infectious Diseases
    • 4.2.1 Aids/Hiv
    • 4.2.1.1 The Aaron Diamond Aids Research Center
    • 4.2.1.2 Alphavax
    • 4.2.1.3 Avant Immunotherapeutics
    • 4.2.1.4 Bavarian Nordic
    • 4.2.1.5 Bionor Immuno
    • 4.2.1.6 Cytrx
    • 4.2.1.7 Dong-A
    • 4.2.1.8 Eurovac
    • 4.2.1.9 Fit Biotech
    • 4.2.1.10 Genecure
    • 4.2.1.11 Genetic Immunity
    • 4.2.1.12 Geovax
    • 4.2.1.13 Glaxosmithkline
    • 4.2.1.14 Immunitor
    • 4.2.1.15 Merck & Co
    • 4.2.1.16 Neovacs
    • 4.2.1.17 Novartis
    • 4.2.1.18 Oxford Biomedica
    • 4.2.1.19 Pharmexa
    • 4.2.1.20 Powdermed
    • 4.2.1.21 Sanofi-Aventis
    • 4.2.1.22 St Jude's Hospital, Memphis
    • 4.2.1.23 Targeted Genetics
    • 4.2.1.24 Therion Biologics
    • 4.2.1.25 The Vaccine Research Center (Vrc)
    • 4.2.1.26 Vaxgen
    • 4.2.1.27 Vical
    • 4.2.1.28 Virax
    • 4.2.1.29 Virionics
    • 4.2.1.30 Wyeth
    • 4.2.1.31 Non-Industry Collaborations
    • 4.2.2 Hepatitis (Excluding Paediatric Combination Vaccines)
    • 4.2.2.1 Hepatitis B (Hbv)
    • 4.2.2.2 Hepatitis C (Hcv)
    • 4.2.2.3 Hepatitis E
    • 4.2.3 Influenza
    • 4.2.3.1 Acambis
    • 4.2.3.2 Alphavax
    • 4.2.3.3 Baxter
    • 4.2.3.4 Crucell
    • 4.2.3.5 Csl
    • 4.2.3.6 Dynport Vaccine Company
    • 4.2.3.7 Generex
    • 4.2.3.8 Glaxosmithkline
    • 4.2.3.9 Iomai
    • 4.2.3.10 Medimmune
    • 4.2.3.11 Merck & Co
    • 4.2.3.12 Nasvax
    • 4.2.3.13 Novartis
    • 4.2.3.14 Novavax
    • 4.2.3.15 Powdermed
    • 4.2.3.16 Protein Sciences
    • 4.2.3.17 Sanofi-Aventis
    • 4.2.3.18 Sinovac Biotech
    • 4.2.3.19 Solvay
    • 4.2.4 Malaria
    • 4.2.5 Meningitis and Pneumococcal Infection
    • 4.2.5.1 China Biopharma
    • 4.2.5.2 Emergent Biosolutions
    • 4.2.5.3 Glaxosmithkline
    • 4.2.5.4 Lg Life Sciences
    • 4.2.5.5 Novartis
    • 4.2.5.6 Sanofi-Aventis
    • 4.2.5.7 Wyeth
    • 4.2.6 Tuberculosis
    • 4.2.7 Other Infectious Diseases
    • 4.2.7.1 Cholera
    • 4.2.7.2 Dengue Fever
    • 4.2.7.3 Ebola and Marburg Infections
    • 4.2.7.4 Helicobacter Pylori
    • 4.2.7.5 Japanese Encephalitis
    • 4.2.7.6 Rabies
    • 4.2.7.7 Rotavirus
    • 4.2.7.8 Typhoid Fever
    • 4.2.7.9 West Nile Virus Infection
    • 4.2.7.10 Yellow Fever
    • 4.3 Other Indications
    • 4.3.1 Addiction
    • 4.3.2 Allergy and Asthma
    • 4.3.3 Autoimmune Diseases
    • 4.3.3.1 Diabetes
    • 4.3.3.2 Rheumatoid Arthritis (Ra)
    • 4.3.4 Bioterrorist Threats
    • 4.3.4.1 Anthrax
    • 4.3.4.2 Botulinum
    • 4.3.4.3 Plague
    • 4.3.4.4 Smallpox
    • 4.3.5 Alzheimer's Disease
    • 4.3.6 Obesity
  • Chapter 5 Company Profiles
    • 5.1 Introduction
    • 5.2 terna Zentaris
    • 5.2.1 Company Overview
    • 5.2.2 Financial Data
    • 5.2.3 Products
    • 5.2.4 R&d Portfolio
    • 5.3 Argos Therapeutics
    • 5.3.1 Company Overview
    • 5.3.2 Financial Data
    • 5.3.3 Products
    • 5.3.4 R&d Portfolio
    • 5.4 Avant Immunotherapeutics
    • 5.4.1 Company Overview
    • 5.4.2 Financial Data
    • 5.4.3 Products
    • 5.4.4 R&d Portfolio
    • 5.5 Avax Technologies
    • 5.5.1 Company Overview
    • 5.5.2 Financial Data
    • 5.5.3 Products
    • 5.5.4 R&d Portfolio
    • 5.6 Bt Pharma
    • 5.6.1 Company Overview
    • 5.6.2 Financial Data
    • 5.6.3 Products
    • 5.6.4 R&d Portfolio
    • 5.7 Bavarian Nordic
    • 5.7.1 Company Overview
    • 5.7.2 Financial Data
    • 5.7.3 R&d Portfolio
    • 5.8 Baxter International
    • 5.8.1 Company Overview
    • 5.8.2 Financial Data
    • 5.8.3 Products
    • 5.8.4 R&d Portfolio
    • 5.9 Cancer Research Technology
    • 5.9.1 Company Overview
    • 5.9.2 Financial Data
    • 5.9.3 Products
    • 5.9.4 R&d Portfolio
    • 5.10 Cell Genesys
    • 5.10.1 Company Overview
    • 5.10.2 Financial Data
    • 5.10.3 Products
    • 5.10.4 R&d Portfolio
    • 5.11 Cellgenix Technologie Transfer
    • 5.11.1 Company Overview
    • 5.11.2 Financial Data
    • 5.11.3 Products
    • 5.11.4 R&d Portfolio
    • 5.12 Celtic Pharma
    • 5.12.1 Company Overview
    • 5.12.2 Financial Data
    • 5.12.3 Products
    • 5.12.4 R&d Portfolio
    • 5.13 Crucell
    • 5.13.1 Company Overview
    • 5.13.2 Financial Data
    • 5.13.3 Products
    • 5.13.4 R&d Portfolio
    • 5.14 Csl
    • 5.14.1 Company Overview
    • 5.14.2 Financial Data
    • 5.14.3 Products
    • 5.14.4 R&d Portfolio
    • 5.15 Cytos Biotechnology
    • 5.15.1 Company Overview
    • 5.15.2 Financial Data
    • 5.15.3 Products
    • 5.15.4 R&d Portfolio
    • 5.16 Dendreon
    • 5.16.1 Company Overview
    • 5.16.2 Financial Data
    • 5.16.3 Products
    • 5.16.4 R&d Portfolio
    • 5.17 Fit Biotech
    • 5.17.1 Company Overview
    • 5.17.2 Financial Data
    • 5.17.3 Products
    • 5.17.4 R&d Portfolio
    • 5.18 Generex
    • 5.18.1 Company Overview
    • 5.18.2 Financial Data
    • 5.18.3 Products
    • 5.18.4 R&d Portfolio
    • 5.19 Geron
    • 5.19.1 Company Overview
    • 5.19.2 Financial Data
    • 5.19.3 Products
    • 5.19.4 R&d Portfolio
    • 5.20 Immunocellular Therapeutics
    • 5.20.1 Company Overview
    • 5.20.2 Financial Data
    • 5.20.3 Products
    • 5.20.4 R&d Portfolio
    • 5.21 Immunofrontier
    • 5.21.1 Company Overview
    • 5.21.2 Financial Data
    • 5.21.3 Products
    • 5.21.4 R&d Portfolio
    • 5.22 Immunomedics
    • 5.22.1 Company Overview
    • 5.22.2 Financial Data
    • 5.22.3 Products
    • 5.22.4 R&d Portfolio
    • 5.23 Immunotope
    • 5.23.1 Company Overview
    • 5.23.2 Financial Data
    • 5.23.3 Products
    • 5.23.4 R&d Portfolio
    • 5.24 Immvarx
    • 5.24.1 Company Overview
    • 5.24.2 Financial Data
    • 5.24.3 Products
    • 5.24.4 R&d Portfolio
    • 5.25 Juvaris Biotherapeutics
    • 5.25.1 Company Overview
    • 5.25.2 Financial Data
    • 5.25.3 Products
    • 5.25.4 R&d Portfolio
    • 5.26 Molmed
    • 5.26.1 Company Overview
    • 5.26.2 Financial Data
    • 5.26.3 Products
    • 5.26.4 R&d Portfolio
    • 5.27 Mologen
    • 5.27.1 Company Overview
    • 5.27.2 Financial Data
    • 5.27.3 Products
    • 5.27.4 R&d Portfolio
    • 5.28 Neovacs
    • 5.28.1 Company Overview
    • 5.28.2 Financial Data
    • 5.28.3 Products
    • 5.28.4 R&d Portfolio
    • 5.29 Newlink Genetics
    • 5.29.1 Company Overview
    • 5.29.2 Financial Data
    • 5.29.3 Products
    • 5.29.4 R&d Portfolio
    • 5.30 Oxford Biomedica
    • 5.30.1 Company Overview
    • 5.30.2 Financial Data
    • 5.30.3 Products
    • 5.30.4 R&d Portfolio
    • 5.31 Pepscan Systems
    • 5.31.1 Company Overview
    • 5.31.2 Financial Data
    • 5.31.3 Products
    • 5.31.4 R&d Portfolio
    • 5.32 Progenics Pharmaceuticals
    • 5.32.1 Company Overview
    • 5.32.2 Financial Data
    • 5.32.3 Products
    • 5.32.4 R&d Portfolio
    • 5.33 Targepeutics
    • 5.33.1 Company Overview
    • 5.33.2 Financial Data
    • 5.33.3 Products
    • 5.33.4 R&d Portfolio
    • 5.34 Therion Biologies
    • 5.34.1 Company Overview
    • 5.34.2 Financial Data
    • 5.34.3 Products
    • 5.34.4 R&d Portfolio
    • 5.35 Vaxon Biotech
    • 5.35.1 Company Overview
    • 5.35.2 Financial Data
    • 5.35.3 Products
    • 5.35.4 R&d Portfolio
    • 5.36 Virionics
    • 5.36.1 Company Overview
    • 5.36.2 Financial Data
    • 5.36.3 Products
    • 5.36.4 R&d Portfolio
    • 4.2.5.6 Sanofi-Aventis
    • 4.2.5.7 Wyeth
    • 4.2.6 Tuberculosis
    • 4.2.7 Other Infectious Diseases
    • 4.2.7.1 Cholera
    • 4.2.7.2 Dengue Fever
    • 4.2.7.3 Ebola and Marburg Infections
    • 4.2.7.4 Helicobacter Pylori
    • 4.2.7.5 Japanese Encephalitis
    • 4.2.7.6 Rabies
    • 4.2.7.7 Rotavirus
    • 4.2.7.8 Typhoid Fever
    • 4.2.7.9 West Nile Virus Infection
    • 4.2.7.10 Yellow Fever
    • 4.3 Other Indications
    • 4.3.1 Addiction
    • 4.3.2 Allergy and Asthma
    • 4.3.3 Autoimmune Diseases
    • 4.3.3.1 Diabetes
    • 4.3.3.2 Rheumatoid Arthritis (Ra)
    • 4.3.4 Bioterrorist Threats
    • 4.3.4.1 Anthrax
    • 4.3.4.2 Botulinum
    • 4.3.4.3 Plague
    • 4.3.4.4 Smallpox
    • 4.3.5 Alzheimer's Disease
    • 4.3.6 Obesity
  • Chapter 5 Company Profiles
    • 5.1 Introduction
    • 5.2 terna Zentaris
    • 5.2.1 Company Overview
    • 5.2.2 Financial Data
    • 5.2.3 Products
    • 5.2.4 R&d Portfolio
    • 5.3 Argos Therapeutics
    • 5.3.1 Company Overview
    • 5.3.2 Financial Data
    • 5.3.3 Products
    • 5.3.4 R&d Portfolio
    • 5.4 Avant Immunotherapeutics
    • 5.4.1 Company Overview
    • 5.4.2 Financial Data
    • 5.4.3 Products
    • 5.4.4 R&d Portfolio
    • 5.5 Avax Technologies
    • 5.5.1 Company Overview
    • 5.5.2 Financial Data
    • 5.5.3 Products
    • 5.5.4 R&d Portfolio
    • 5.6 Bt Pharma
    • 5.6.1 Company Overview
    • 5.6.2 Financial Data
    • 5.6.3 Products
    • 5.6.4 R&d Portfolio
    • 5.7 Bavarian Nordic
    • 5.7.1 Company Overview
    • 5.7.2 Financial Data
    • 5.7.3 R&d Portfolio
    • 5.8 Baxter International
    • 5.8.1 Company Overview
    • 5.8.2 Financial Data
    • 5.8.3 Products
    • 5.8.4 R&d Portfolio
    • 5.9 Cancer Research Technology
    • 5.9.1 Company Overview
    • 5.9.2 Financial Data
    • 5.9.3 Products
    • 5.9.4 R&d Portfolio
    • 5.10 Cell Genesys
    • 5.10.1 Company Overview
    • 5.10.2 Financial Data
    • 5.10.3 Products
    • 5.10.4 R&d Portfolio
    • 5.11 Cellgenix Technologie Transfer
    • 5.11.1 Company Overview
    • 5.11.2 Financial Data
    • 5.11.3 Products
    • 5.11.4 R&d Portfolio
    • 5.12 Celtic Pharma
    • 5.12.1 Company Overview
    • 5.12.2 Financial Data
    • 5.12.3 Products
    • 5.12.4 R&d Portfolio
    • 5.13 Crucell
    • 5.13.1 Company Overview
    • 5.13.2 Financial Data
    • 5.13.3 Products
    • 5.13.4 R&d Portfolio
    • 5.14 Csl
    • 5.14.1 Company Overview
    • 5.14.2 Financial Data
    • 5.14.3 Products
    • 5.14.4 R&d Portfolio
    • 5.15 Cytos Biotechnology
    • 5.15.1 Company Overview
    • 5.15.2 Financial Data
    • 5.15.3 Products
    • 5.15.4 R&d Portfolio
    • 5.16 Dendreon
    • 5.16.1 Company Overview
    • 5.16.2 Financial Data
    • 5.16.3 Products
    • 5.16.4 R&d Portfolio
    • 5.17 Fit Biotech
    • 5.17.1 Company Overview
    • 5.17.2 Financial Data
    • 5.17.3 Products
    • 5.17.4 R&d Portfolio
    • 5.18 Generex
    • 5.18.1 Company Overview
    • 5.18.2 Financial Data
    • 5.18.3 Products
    • 5.18.4 R&d Portfolio
    • 5.19 Geron
    • 5.19.1 Company Overview
    • 5.19.2 Financial Data
    • 5.19.3 Products
    • 5.19.4 R&d Portfolio
    • 5.20 Immunocellular Therapeutics
    • 5.20.1 Company Overview
    • 5.20.2 Financial Data
    • 5.20.3 Products
    • 5.20.4 R&d Portfolio
    • 5.21 Immunofrontier
    • 5.21.1 Company Overview
    • 5.21.2 Financial Data
    • 5.21.3 Products
    • 5.21.4 R&d Portfolio
    • 5.22 Immunomedics
    • 5.22.1 Company Overview
    • 5.22.2 Financial Data
    • 5.22.3 Products
    • 5.22.4 R&d Portfolio
    • 5.23 Immunotope
    • 5.23.1 Company Overview
    • 5.23.2 Financial Data
    • 5.23.3 Products
    • 5.23.4 R&d Portfolio
    • 5.24 Immvarx
    • 5.24.1 Company Overview
    • 5.24.2 Financial Data
    • 5.24.3 Products
    • 5.24.4 R&d Portfolio
    • 5.25 Juvaris Biotherapeutics
    • 5.25.1 Company Overview
    • 5.25.2 Financial Data
    • 5.25.3 Products
    • 5.25.4 R&d Portfolio
    • 5.26 Molmed
    • 5.26.1 Company Overview
    • 5.26.2 Financial Data
    • 5.26.3 Products
    • 5.26.4 R&d Portfolio
    • 5.27 Mologen
    • 5.27.1 Company Overview
    • 5.27.2 Financial Data
    • 5.27.3 Products
    • 5.27.4 R&d Portfolio
    • 5.28 Neovacs
    • 5.28.1 Company Overview
    • 5.28.2 Financial Data
    • 5.28.3 Products
    • 5.28.4 R&d Portfolio
    • 5.29 Newlink Genetics
    • 5.29.1 Company Overview
    • 5.29.2 Financial Data
    • 5.29.3 Products
    • 5.29.4 R&d Portfolio
    • 5.30 Oxford Biomedica
    • 5.30.1 Company Overview
    • 5.30.2 Financial Data
    • 5.30.3 Products
    • 5.30.4 R&d Portfolio
    • 5.31 Pepscan Systems
    • 5.31.1 Company Overview
    • 5.31.2 Financial Data
    • 5.31.3 Products
    • 5.31.4 R&d Portfolio
    • 5.32 Progenics Pharmaceuticals
    • 5.32.1 Company Overview
    • 5.32.2 Financial Data
    • 5.32.3 Products
    • 5.32.4 R&d Portfolio
    • 5.33 Targepeutics
    • 5.33.1 Company Overview
    • 5.33.2 Financial Data
    • 5.33.3 Products
    • 5.33.4 R&d Portfolio
    • 5.34 Therion Biologies
    • 5.34.1 Company Overview
    • 5.34.2 Financial Data
    • 5.34.3 Products
    • 5.34.4 R&d Portfolio
    • 5.35 Vaxon Biotech
    • 5.35.1 Company Overview
    • 5.35.2 Financial Data
    • 5.35.3 Products
    • 5.35.4 R&d Portfolio
    • 5.36 Virionics
    • 5.36.1 Company Overview
    • 5.36.2 Financial Data
    • 5.36.3 Products
    • 5.36.4 R&d Portfolio
  • List of Tables
    • Table 1.1 Global Deaths by Cancer Type
    • Table 1.2 Reduction in Diseases in Europe between 1998 and 200426
    • Table 2.1 Launched Vaccines Currently Available by Indication
    • Table 5.1 Financial Data for terna Zentaris
    • Table 5.2 Financial Data for Avant Immunotherapeutics 2003-2006 (US$ Million)
    • Table 5.3 Financial Data for Avax Technologies (US$ Million)
    • Table 5.4 Financial Data for Bavarian Nordic 2003-2006 (Dkr Million)
    • Table 5.5 Financial Data for Baxter International 2003-2006 (US$ Million)125
    • Table 5.6 Financial Data for Cell Genesys 2002-2006 (US$ Million)
    • Table 5.7 Financial Data for Crucell (€ Million)
    • Table 5.8 Financial Data for Csl 2002-2006 (Aus$ Million)
    • Table 5.9 Financial Data for Cytos Biotechnology 2002-2006 (Swfr Million)
    • Table 5.10 Financial Data for Dendreon 2002-2006 (US$ Million)
    • Table 5.11 Financial Data for Generex 2002-2006 (US$ Million)
    • Table 5.12 Financial Data for Geron 2002-2006 (US$ Million)
    • Table 5.13 Financial Data for Ict (US$ Million)
    • Table 5.14 Financial Data for Immunomedics 2002-2006 (US$ Million)
    • Table 5.15 Financial Data for Mologen (€ Million)158
    • Table 5.16 Financial Data for Oxford Biomedica 2002-2006 ( Million)
    • Table 5.17 Financial Data for Progenics Pharmaceuticals 2003-2006 (US$ Million) Figure 1.1 Trends in The Vaccine Industry
    • Figure 1.2 Trends in The Development of Prophylactic Vaccines
    • Figure 1.3 Trends in The Development of Therapeutic Vaccines
    • Figure 1.4 Trends in The Development of Recombinant Vaccines